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ABSTRACT
A group of influenza experts from Argentina and Brazil got 
together to discuss the burden of influenza in children, 
review current vaccine coverage rates in both countries, 
analyze vaccine effectiveness, and discuss strategies to 
improve prevention. Active surveillance of respiratory 
viruses is carried out nationwide in both countries. Years 
2014 and 2015 were mild influenza seasons; influenza virus 
type A/H3N2 prevailed, whereas type B represented less than 
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30% of isolates. Trivalent inactivated influenza vaccine is 
included in National Immunization Programs for 1) 
 children 6 months to 2 years old in Argentina; 2) children 
6 months to 5 years old in Brazil; and 3) all high-risk indi-
viduals. Coverage rates in both countries were about 80% 
(albeit lower for the second dose). Experts from both coun-
tries proposed the following strategies to improve preven-
tion: 1) increase surveillance; 2) assess effectiveness and 
long-term safety of influenza vaccines; 3) reinforce vacci-
nation programs in order to increase coverage rates; and 4) 
consider introducing more effective vaccines, such as adju-
vanted trivalent vaccines. In Argentina, estimating case-
fatality rates was also recommended. Other proposed 
actions included enhancing education of health profession-
als and the lay community, and better use of communica-
tion resources to raise awareness of the burden of influenza 
and promote vaccine uptake.
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Worldwide, influenza causes a substantial health 
burden in children, particularly infants and young 
children. In the United States, despite universal in-
fluenza immunization, reported hospitalizations 
rates for children in 2014–2015 were 50–60 per 100 
000, and 100–170 influenza-related pediatric deaths 
occurred that same season (1). Most hospitalizations 
(80%) were caused by influenza A subtype H3N2 
(A/H3N2), but influenza B accounted for one-third 
of deaths (2).
On November 18, 2015, influenza experts from 
Argentina and Brazil participated in a roundtable 
meeting in Rio de Janeiro to 1) assess the burden 
of influenza illness in children; 2) analyze vaccine 
coverage and vaccine effectiveness; and 3) discuss 
strategies to improve prevention. This article summa-
rizes the results of the meeting (“Looking into the 
Future in the Prevention of Influenza in Children: 
How Will New Vaccines Provide Better Protection”), 
which was organized by a nonprofit organization 
known as FIDEC (Fighting Infectious Diseases in 
Emerging Countries) (Miami, Florida, United States). 
The working group of influenza experts discussed 
 influenza epidemiology in Argentina and Brazil, in-
fluenza immunization programs, coverage rates, and 
evidence for vaccine effectiveness. The experts 
 reviewed the rationale for routine immunization in 
children, discussed challenges in achieving effective 
control programs, and proposed strategies and ac-
tions to improve protection.
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EPIDEMIOLOGY AND BURDEN OF 
INFLUENZA
Argentina
In Argentina, influenza surveillance data are pro-
vided by the National Laboratory Surveillance System 
(Sistema Nacional de Vigilancia de Salud, SNVS). In 2014, 
the system reported 2 308 influenza virus isolates 
(77% type A and 23% type B) (3). Up until epidemio-
logical week 43 of 2015, the system reported 2 049 
 isolates: 91% type A (52% H3, 10% H1N1pdm09, 
and 38% not subtyped) and 9% type B (mainly 
Yamagata) (3).
The burden of influenza can be assessed through 
acute respiratory infection hospitalizations. At a chil-
dren’s hospital in Buenos Aires (Hospital de Niños 
Ricardo Gutierrez), during 2000–2013, influenza ac-
counted for 7% of all respiratory virus isolations (4). In 
a pharmaco-economic study at the same institution, 
estimated annual costs attributable to influenza in chil-
dren under 5 years old ranged from US$ 250 000 to US$ 
350 000 (5). Influenza mortality data are not available 
for the same period for Argentina.
Brazil
In Brazil, disease surveillance covers influenza-like 
illness (ILI) (at sentinel sites) and severe acute respi-
ratory syndrome (SARS) (in patients admitted to in-
tensive care units, and in universal SARS surveil-
lance). In 2014–2015, the influenza seasons were mild 
(6, 7), with type A/H3N2 predominant and late circu-
lation of type B. In 2015, approximately 12 000 ILI 
samples were processed; 25% were positive for a 
respiratory virus, and 50% of those were influenza 
(55% A/H3N2, 30% B, 8% non-subtyped A, and 7% 
A/H1N1) (7). Influenza was more prevalent in chil-
dren more than 4 years old, and type B predominated 
in adolescents. The South and Southeast regions 
accounted for most of the positive samples, with 
A/H3N2 prevailing, and co-circulation of A/H3N2, 
A/H1N1, and B occurring in the South region. Based 
on the results of the universal SARS surveillance, 8% 
of 12 300 samples were influenza viruses. In São 
Paulo, 20% of influenza-related hospitalizations were 
due to type B (7).
A total of 1 420 SARS-related deaths were reported 
up to October 2015, with 151 (11%) caused by influ-
enza (45% A/H3N2, 23% B, 17% A/H1N1, and 15% 
non-subtyped A) (7). The influenza mortality rate 
was 0.08 per 100 000 population, and 70% had at least 
one risk factor (age over 60 years, chronic cardiovas-
cular or pulmonary condition, diabetes, or obesity). 
Only 11% had received a flu vaccine. A/H1N1 had 
a higher case-fatality rate than other influenza 
viruses.
In a study of respiratory viral infections in children 
under 2 years old hospitalized at the Santa Casa 
Hospital in São Paulo, from 2008 to 2010 (8), 10% of all 
respiratory isolates were influenza viruses and 50% of 
children had underlying health conditions.
ROUTINE IMMUNIZATION, COVERAGE 
RATES, AND VACCINE EFFECTIVENESS
Argentina
 In Argentina, trivalent inactivated influenza vac-
cine (IIV3) was introduced into the National 
Immunization Program (NIP) in 2011 for children 6 
months to 2 years old and other target groups includ-
ing 1) high-risk individuals (e.g., those with chronic 
respiratory and cardiovascular conditions, diabetes, 
immunocompromising conditions, etc.); 2) pregnant 
or postpartum women; 3) health care workers; and 4) 
adults 65 years old and older (9). From 2011 to 2015, 
vaccine coverage in young children (6 months to 2 
years old) ranged between 72% (for the first dose) 
and 50% (for the second) (9).
IIV3 effectiveness was assessed through a case-con-
trol study carried out at three pediatric hospitals (10). 
Although the total number of cases was low (38 cases 
and 92 controls), preliminary effectiveness was 73% in 
children 6 months to 2 years old. Results from the Pan 
American Health Organization (PAHO) Network for 
Evaluation of Influenza Vaccine Effectiveness in the 
Latin America and Caribbean Region (Red para la 
Evaluación de Vacunas En Latino América y el Caribe–in-
fluenza, REVELAC-i) assessing influenza vaccine effec-
tiveness showed a lower protection rate (48%) for the 
prevention of severe infections in children under 5 
years old (11).
Vaccination of pregnant women can help prevent 
influenza in newborns and young infants (12). In 2015, 
IIV3 coverage in this population exceeded 90% (3). 
A study carried out in Argentina using the influenza 
A/H1N1 MF59-adjuvanted vaccine (13) demonstrated 
that vaccinated pregnant women had a lower risk 
of 1) giving birth to low-weight babies (odds ratio 
(OR): 0.74) and 2) premature deliveries (OR: 0.79). 
Furthermore, vaccination was not associated with 
 adverse perinatal or maternal events.
Brazil
In Brazil, influenza immunization is routinely ad-
ministered to children 6 months to 5 years old, 
adults 60 years old and older, pregnant or postpar-
tum women, health care workers, the indigenous 
population, individuals in prison, and high-risk 
groups (e.g., those with chronic respiratory or car-
diovascular diseases, diabetes, immunocompromis-
ing conditions, etc.) (14). Overall, in 2011–2014, vac-
cination coverage exceeded 80% in all groups (15), 
and in 2015 approximately 50 million people (25% of 
the population) were immunized (14). Most vaccines 
used during the 2016 influenza season were manu-
factured locally by the Instituto Butantan (São 
Paulo).
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RATIONALE AND HURDLES OF ROUTINE 
INFLUENZA IMMUNIZATION IN CHILDREN
The burden of influenza in children is substantial 
and hospitalization rates are highest among the young-
est children (16, 17). Notably, half of flu-related hospi-
talizations and deaths occur in previously healthy 
children, so a vaccination strategy that only includes 
children with comorbidities does not seem to be effec-
tive (18).
Influenza immunization in children is the most ef-
fective way to prevent disease, affording both direct 
and indirect protection. The protective effect of the 
vaccine depends largely on the match between vaccine 
strains and circulating viruses. As children are usually 
the family members who bring influenza into their 
household, vaccinating children could help mitigate 
outbreaks (19). One health care model showed that 
vaccinating 20% of schoolchildren had a greater impact 
on flu-related mortality than vaccinating 90% of the el-
derly (20). When influenza immunization of school-
children was introduced in Japan, all-cause deaths, as 
well as influenza and pneumonia-related deaths, were 
significantly reduced in all age groups (21), and when 
vaccination was stopped, mortality rates increased, es-
pecially in the elderly.
There are, however, several hurdles to introducing 
an early childhood influenza control program. First, 
there are limited vaccine options. IIV3s have moderate 
efficacy in young children (22), and do not induce per-
sistent immune response. Inactivated influenza vac-
cines, quadrivalent (IIV4s) offer broader protection 
against the two B lineages, which usually co-circulate 
yet alternate in dominance (2). Although B viruses pre-
dominate in children, they are a significant cause of 
hospitalizations and deaths in all age groups. Use of 
IIV4 could reduce a mismatch between a vaccine and 
circulating B lineages, but the benefits would be 
modest (23). Adjuvanted IIV3s (aIIV3s) are more effec-
tive than non-adjuvanted vaccines. In a trial of MF59-
adjuvanted IIV3 in 4 700 children 6–72 months old 
(24), efficacy was 85% (the highest ever reported 
in children 6–24 months old) and persisted after 
the second dose, and there were no safety issues. 
According to one study, the correlate of protection 
threshold is higher in children than in adults (25); for 
example, titers of 1:110 in children and 1:40 in adults 
were both associated with 50% clinical protection. In 
Canada, aIIV3 is licensed for use in infants and young 
children 6–24 months old due to its superior immuno-
genicity and acceptable safety profile (26). At the 
roundtable meeting, use of the live attenuated vaccine 
was also discussed, but as this vaccine is not available 
in Argentina or Brazil, the information was not in-
cluded in this report.
A second hurdle to introducing a childhood influ-
enza control program is related to safety and reduced 
confidence due to adverse events following immuniza-
tion (AEFIs), a problem mostly seen in Europe and 
North America. Unexpected AEFIs with two flu 
 vaccines have had a negative impact (27, 28). In addi-
tion, poor vaccine performance could discredit the in-
tegrity of the NIP and dampen the success of other 
routine vaccines.
A third hurdle concerns funding requirements. 
Introducing flu vaccine into an NIP requires evidence 
of cost-effectiveness involving high vaccine efficacy; 
reasonable cost (with drawbacks including the need 
for two-dose priming and/or annual revaccination); 
and negligible AEFI costs. Currently, 29 countries in 
Latin American but only seven in Europe have routine 
influenza childhood immunization programs, and 
vaccine uptake in developed countries does not sur-
pass 30%.
At the meeting, various solutions were suggested to 
overcome these hurdles, including 1) using more effi-
cacious vaccines; 2) building greater confidence in 
safety by extending post-licensure surveillance; and 3) 
making public programs more flexible by broadening 
the interval of the two-dose schedule, irrespective of 
the season, and expanding school delivery programs 
to include children 1–5 years old.
CHALLENGES IN INFLUENZA PREVENTION 
IN ARGENTINA AND BRAZIL
The meeting participants agreed that assessing the 
burden of disease and the impact of vaccination is 
more difficult for influenza than for other vaccine- 
preventable diseases because influenza cannot be 
eradicated, symptoms are nonspecific, cases are not 
usually virologically tested, and herd protection is 
difficult to measure.
Immunization rates are decreasing in Argentina and 
Brazil (9, 15) for flu as well as other vaccines, although 
both countries still retain the highest influenza vacci-
nation rates worldwide. One reason for this down-
ward trend is parent misinformation. Parents often see 
influenza as a mild disease and thus view the influ-
enza-like symptoms from the vaccines as outweighing 
any benefits (29). In addition, people get tired of 
having to get shots every year. The growing influence 
of local anti-vaccination advocacy groups is also a 
cause for concern.
Another factor in the lower coverage is the logis-
tics related to limited staffing for administering rou-
tine vaccines in a crowded childhood immunization 
calendar.
Education of health care workers is another problem 
that needs to be tackled. As shown in a study evaluat-
ing missed opportunities for flu vaccination, from the 
parents’ perspective (30), the main reason for the lower 
coverage was a lack of information from health care 
workers, who were not recommending the vaccine. In 
Argentina, few specialists recommend influenza vacci-
nation for children with chronic comorbidities at high-
risk for flu-related complications.
In discussing the best vaccine options, the meeting 
participants emphasized the superiority of the aIIV3 
compared to the IIV4. While the second B strain may 
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add 15% efficacy, leading to an overall IIV4 efficacy of 
60%–65%, the efficacy of adjuvanted vaccines exceeds 
80%, while also providing protection for mismatched B 
lineage. In Brazil, although the IIV4 became available 
in the private market in 2015, the Ministry of Health is 
not considering incorporating it into the NIP in the 
near future.
Safety concerns for use of repetitive doses of adju-
vanted vaccines in young children were also  addressed. 
Canada has licensed the aIIV3 with limited indication 
in the youngest age group (6–24 months) (26). In 
Argentina, the national immunization committee has 
resolved to continue using IIV3 and will consider in-
corporating adjuvanted vaccines in the future (a tech-
nology transfer agreement will enable local vaccine 
production).
STRATEGIES AND ACTIONS TO IMPROVE 
PROTECTION
Following the roundtable meeting discussions the 
participants proposed strategies to improve disease 
surveillance and actions to increase protection in 
Argentina and Brazil.
Surveillance strategies
Recommended surveillance strategies included 1) 
developing an influenza monitoring system and uni-
fied national database (both countries) and 2) estimat-
ing case-fatality rates (in Argentina only).
Protection actions
Recommended protective actions were grouped into 
three categories: 1) vaccination, 2) education, and 3) 
communication. Proposed vaccination actions included 
1) conducting continued surveillance of effectiveness of 
inactivated vaccines; 2) estimating coverage in different 
populations; 3) increasing vaccination in pregnant 
women for protection of young infants; 4) promoting 
vaccination at childcare centers; 5) carrying out long-
term vaccine safety surveillance to avoid AEFIs; 
6) considering the introduction of aIIV3s for infants 
and children; and 7) considering universal vaccination 
of schoolchildren to gain herd protection (in Brazil; in 
Argentina, this strategy was not deemed feasible in the 
short-term because the main objective there is to reduce 
morbidity and mortality in high-risk groups rather 
than reducing viral circulation). Proposed education 
actions included: 1) enhancing education of health pro-
fessionals; 2) reinforcing the nurse’s role in promoting 
immunization and delivering vaccines; 3) raising 
awareness of the risk of influenza in the population; 
4) targeting high-risk groups, working with scientific 
societies and  specialists; and 5) strengthening the phy-
sician–parent relationship and helping parents under-
stand the risk/benefits of vaccines. In the same vein, 
the following communication activities were suggested 
to raise awareness of the value of vaccines: 1) using 
media to communicate the risks of vaccine-preventable 
diseases; 2) using the Internet and social media to pro-
mote vaccine uptake; and 3) using reminder cards for 
vaccination schedules.
CONCLUSIONS
The high burden of influenza in children in Argentina 
and Brazil calls for sustained efforts to improve protec-
tive measures. There is a need for more effective flu 
vaccines for infants and young children. Surveillance 
programs should continue to 1) monitor for changes in 
circulating viruses and 2) assess vaccine effectiveness 
and safety. Increasing vaccine coverage levels, intro-
ducing adjuvanted vaccines, and continuing the devel-
opment of more effective vaccines are all goals that 
should be pursued.
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RESUMEN Expertos en influenza de Argentina y Brasil reunidos en un grupo de tra-
bajo evaluaron la carga de enfermedad de influenza en niños, analizaron 
las coberturas vacunales, la efectividad de las vacunas y discutieron 
estrategias para mejorar la prevención. En ambos países se realiza vigilan-
cia de virus respiratorios en todo el territorio. Las últimas temporadas de 
gripe fueron leves, con predominio de influenza A H3N2, influenza B rep-
resentó menos del 30% de los aislamientos (con co-circulación de ambos 
linajes). La vacuna de influenza inactivada trivalente está incluida en el 
Programa Nacional de Inmunizaciones en niños entre 6 meses-2 años en 
Argentina y hasta los 5 años en Brasil, y en niños mayores con factores de 
riesgo. Las coberturas alcanzan 80% (menor para la segunda dosis). 
Las estrategias propuestas incluyen incrementar la vigilancia de la 
enfermedad y estimar la tasa de letalidad (Argentina), realizar vigilan-
cia de efectividad y seguridad de las vacunas, fortalecer los programas 
para aumentar las coberturas y considerar incorporar nuevas vacunas 
más eficaces. También se discutieron acciones de educación, tanto en la 
comunidad como en los trabajadores de la salud, y de comunicación 
para concientizar sobre el impacto de influenza en la población y la 
importancia de su prevención.
Epidemiología y 
 prevención de la 
gripe en niños en 
Argentina y Brasil
Palabras clave Orthomyxoviridae; pediatría; vacunas contra la influenza; Argentina; 
Brasil; América del Sur.
RESUMO Um grupo de especialistas em influenza da Argentina e do Brasil reu-
niu-se para discutir o ônus da influenza em crianças, analisar os índices 
de cobertura vacinal nos dois países, analisar a efetividade das vacinas 
e discutir estratégias para melhorar a prevenção. A vigilância ativa de 
vírus respiratórios é realizada em âmbito nacional em ambos os 
países. Nos anos 2014 e 2015, as temporadas de gripe foram leves; o tipo 
A/H3N2 do vírus da influenza prevaleceu, enquanto que o tipo B rep-
resentou menos de 30% dos isolados. A vacina trivalente inativada 
contra a influenza está incluída nos programas nacionais de vacinação 
para 1) crianças de 6 meses a 2 anos de idade na Argentina; 2) crianças 
de 6 meses a 5 anos de idade no Brasil; e 3) todos os indivíduos de alto 
risco. As taxas de cobertura em ambos os países foram de aproximada-
mente 80% (porém menores para a segunda dose). 
Os especialistas de ambos os países propuseram as seguintes estraté-
gias para melhorar a prevenção: 1) aumentar a vigilância; 2) avaliar a 
efetividade e segurança a longo prazo das vacinas contra a influenza; 3) 
reforçar os programas de vacinação para aumentar as taxas de cober-
tura; e 4) considerar a possibilidade de introduzir vacinas mais eficazes, 
como as vacinas tríplices com adjuvante. Recomendou-se também cal-
cular as taxas de letalidade na Argentina. Outras ações propostas 
incluíram melhorar a capacitação dos profissionais da saúde e da comu-
nidade leiga e melhorar o uso de recursos em comunicação para 
 au mentar a conscientização sobre o ônus da influenza e promover a 
vacinação.
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